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R&D EVALUATION 
€ Commission of the European Communities 
THE  EVALUATION  OF  THE  CONCERTED  ACTIONS 
OF  THE  COMMUNITY'S  FIRST  -
MEDICAL  RESEARCH  PROGRAMME  1978-1981 
•  Cellular Ageing and Decreased Functional 
Capacity of Organs 
•  Extracorporeal  OOCygenation 
•  The  Registration of Congenital  Abnormalities 
and Twins 
1.  BACKGROUND 
This  evaluation was  carried out in the context of the Commission's 
current  efforts to  develop a  global  system for  evaluating the results 
of Community  R&D  programmes.  This is the fifth external  evaluation of 
Community  research programmes  during which  evaluation methods  have  been 
experimentally applied to different types of Community  research actions. 
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2.  THE  EVALUATION  METHOD 
These are the first of the Community's  research activities known  as 
concerted actions to be  evaluated externally.  Research in the  form 
of concerted actions is decided upon,  carried out  and totally financed 
by-national  institutes,  while the Commission  only provides  and 
organises  the  coordination of the research •.  The  method which was 
applied for the first time was  in the form  of a  "Hearing".  Covering 
a  period of three days,  a  panel  of external  and independent  experts, 
questioned leading representatives involved in the projects being 
evaluated. 
3.  SCOPE  OF  THE  EVALUATION 
The  scope of the evaluation was  limited,  given the time available 
and the restricted role of the  Commission  in this type of research· 
action,  to  the assessment of the value  and  impact  of the  concerted 
actions and of the effectiveness of the  coordination.  The  panel  was 
also invited to  make  recommendations  for  future actions in the field 
and  to  comment  on  the method  applied. 
4.  COMPOSITION  OF  THE  PANEL 
Sir Gordon  Wolstenholme  (Chairman)  Royal  College of Physicians, 
London  (UK) 
Dr.  Ronald  Akehurst  Institute of Social  and Economic 
Research,  University of York  (UK). - 3  -
Dr.  Lise Cedard  Laboratoire de  Chimie  Hormonale  des 
Maternites  Cochin  de  Port  Royal, 
Paris  (F) 
Professor v.  P.  Eijsvoogel  Central  Laboratory of the Netherlands 
Red  Cross  Blood Transfusion Service  (N) 
Professor Niels  T,ygstrup  University Hospital,  Copenhagen  (DK) 
Professor von Manger-Koenig  Bundesministerium fUr Jugend,  Familie 
und  Gesundheit,  Bonn  (D) 
Professor A.  Zanchetti  Istituto di  Ricerche  Cardiovascolari 
Giorgini Sisini,  Universita  di Milano  (I) 
5.  EXECUI'IVE  SUMMARY 
Outlined below is a  summary* of the findings of the evaluation panel 
as  submitted to  the Commission  by its Chairman,  Sir Gordon  \'lolstenholme. 
"The  Commission  was  wise and  fortunate in the  choice of the first  3 
examples of Concerted Action in Medical  and Public Health Research. 
"Cellular Ageing research has  predominantly important  social implications; 
Extracorporeal  ~genation emphasises  the dramatically life-saving 
potentialities of new  advances  in technology;  and registration of con-
genital abnormalities is an essential  exercise in epidemiology which 
opens up possibilities of much  needed preventive measures  and safe-
guards  for  environmental  foeto-toxicity. 
"Apart  from  early delays in implementation,  and  continuing hindrances 
from  unnecessarily restrictive financial  regulations,  the First 
*The full report is available under  the reference  EUR  7730 - 4  -
Programme  of Concerted Actions has  been responsibly and  efficiently 
managed.  The  scientific research,  headed by the Project Leaders,  has 
been  competently and  imaginatively conducted. 
"Member  States need to  enter into greater  commitment  in regard to  the 
work  of the Committee  for Medical  and  Public Health Research  (CRM). 
Too  little is known  in Member  States about  the Concerted Action 
programmes,  and information of relevant research progress in the Member 
States is slow to reach the Concerted Action Committees  (COMACs).  A 
reinvigorated  CRM  should provide the active interface for the  flow of 
information in both directions. 
"Periodic evaluation of Concerted Actions  should be  an integral part of 
their organization,  and  can be  carried out in a  si~ple and inexpensive 
manner. 
"Concerted Action has been shown  to be the method  by which  Community 
intervention and moderate financial  support in medical  and health 
research can best  support  the national research policies of Member 
States. - 5  -
"RECOMMENDATIONS 
Many  points of recommendation  have  been implicit in the report.  A 
further,  weighty consideration is provided by the wealth of planning 
which has  gone  into a  Third Programme  of Concerted Action.  The  Panel's 
recommendations  can  therefore be  simple: 
i)  Concerted Action is particularly suited to  the support of 
medical  and health research by the Community  and should be 
continued and  expanded. 
ii)  The  Committee  on  Medical  and  Public Health Research  EcRM)  has 
shown  prescience,  imagination and responsibility in the choice 
of topics,  and  should be  given greater support within Member 
States in regard to expertise,  authority and national 
recognition of progress. 
iii)  A more  assured and  confident  CRM  should in turn strengthen the 
constitution of Concerted Action Committees  (COMACs),  and  then 
there should be  a  closer ongoing relationship between  CRM  and 
C<HA.Cs. 
iv)  The  nomination by Member  States of institutes and individuals 
to  take part in Concerted Action should be subject to scrutiny 
and approval  by other Member  States within  CRM,  in fUll  con-
sultation with the appropriate Project Leader. 
v)  The  first 3  Project  Leaders are impressively competent,  and the 
vital importance of the personal qualities of the Project  Leader 
must  be kept  well  in mind  in the future selection of other 
Leaders. 
vi)  Project  Leaders  should be  entrusted with greater financial - 6  -
responsibility and  freedom,  in the interests of speed of 
decision and action. 
vii)  The  Commission  should take steps to ensure the development 
within the Community  of any technological  and industrial 
advances arising from  research supported by the Community. 
viii)  Periodic evaluation should be included in all  programmes  of 
Concerted Action,  and should be repeated every 2  to  3 years. 
ix)  Evaluation  can be  performed adequately by a  small  team of 
external  peer assessors,  using the Hearing method  supported 
by ample  documentation.  " 